Working with Arup to prepare a strategic assessment of the GlaxoSmithKline plant at Coleford, in the Forest of Dean. The plant is a legacy of the Beechams part of the business producing Ribena and Lucozade. Substantial investment is proposed over the next 15 years and GSK wants to ensure that there is a properly conceived strategic plan to back up their investment.

The proposals suggest a phased redevelopment, replacing individual production lines as they become obsolete until the entire production area is replaced. Key high value modern assets such as the bottle blowing plant and blends facility are retained and incorporated into the design.
The new facility will consist of a rational linear layout of production lines with improved flexibility of packaging and rationalised vehicle movements leading to improved safety and efficiency.
Adoption of a BREEAM Outstanding target for the facility ensures that sustainability is designed in from the outset.